10:12:24 Friday, March 29
Politics Economy Agriculture Society IT Education Medicine Religion Communal Services Incidents Crime Culture Sport

Dmitry Boldov: Penza “Biosintez” ready to develop international partnerships

13:57 | 04.02.2016 | Economy

Print

Penza, 4 February 2016. PenzaNews. The pharmaceutical production company “Biosintez” based in the Penza region successfully completed the audit of its capabilities by a large Indian pharmaceutical producer in early February 2016, the general director of “Biosintez” Dmitry Boldov told PenzaNews agency.

Photo: Biosintez.com

© PenzaNewsBuy the photo

According to him, the company already has successful experience of contract medicine production for Russian and foreign firms.

“Thanks to the investment-funded modernization project, the enterprise now has cutting-edge production areas that brought us an all-round increase in production capabilities. Presently, ‘Biosintez’ has its own GMP-certified production line of pharmaceutical ingredients; it producers medicinal injection and infusion solutions, pre-filled syringes, pills, injection solution powders, capsules, suppositories, ointments, creams and gels,” Dmitry Boldov explained.

He pointed out that the capabilities of GMP-certified production facilities per year are: up to 34 million bottles and polymer containers of blood substitutes, approximately 22 million packages of ointments and suppositories, about 35 million packages of ampules, as well as 102 million cartriges of injection solution powders and 2.4 billion pills.

“In addition, ‘Biosintez’ was one of the first to undergo national GMP certification (GOST R 52249-2009). We are working on obtaining European GMP certification as well. We already received European certification for production of injection and infusion solutions, aseptic production of antibiotic injection solution powders,” said the general director of the company.

As Dmitry Boldov explained, obtaining GMP certification allowed the enterprise to improve its position on Russian and foreign markets, as well as streamline and accelerate the registration process for its pharmaceuticals abroad and the customs declaration process.

“For ‘Biosintez,’ development of new and generic drugs, as well as improvement of pharmaceutical production procedures and technologies, is an important objective. The enterprise has its own R&D department with certified labs and a standalone experimental pilot production line,” he noted.

He stressed that “Biosintez” has vast potential for cooperation with other companies in joint and contract production at the present time as foreign production facilities in Russia are made local.

“Under the ‘no third wheels’ program, accelerating the shift to local production of pharmaceuticals by foreign companies in Russia will help avoid shortage of unique and rare medication in the state procurement system,” concluded the general director of “Biosintez.”

Lastest headlines
Read also